AGP Executive Report
Last update: 7 hours agoBiotech Licensing: IMPACT Therapeutics signed an exclusive licensing deal with Pharmanovia for senaparib across Europe, MENA, Australia and New Zealand, with up to EUR 423.5m in upfront, milestones and royalties, and EMA acceptance for 1L maintenance therapy expected to land in 2H26. EU Health Regulation: Pfizer and BioNTech secured EU marketing authorisation for their 2026-2027 XFG-adapted COVID-19 vaccine, with manufacturing already underway for the coming respiratory season; the authorisation covers all EU states plus Liechtenstein and Norway. Energy & Industry Finance: The European Commission is offering interest-free EUR 1.5bn loans to scale EV battery production, with projects needing at least 10 GW annual capacity and funding up to 60% of eligible costs. Cross-Border Logistics: Europe’s heatwave is now hitting shipping too, as low Rhine and Danube levels threaten cargo capacity and disrupt industrial supply chains. Liechtenstein Industry Link: Oerlikon Balzers (Balzers) promoted its Baldia CVD diamond coatings for composite machining, targeting abrasive wear reduction and longer tool life. Crypto Compliance Watch: Binance’s Android app reportedly vanished from Google Play in some EU markets as MiCA rules fully took effect, while ESMA’s MiCA register added 15 new crypto-asset service providers, lifting it to 309.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
